Vorinostat


Vorinostat
Systematic (IUPAC) name
N-hydroxy-N'-phenyl-octanediamide
Identifiers
CAS number	149647-78-9
ATC code	?
PubChem	5311
Chemical data
Formula	C₁₄H₂₀N₂O₃
Mol. weight	264.32 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	71%
Metabolism	Hepatic glucuronidation and oxidation CYP system not involved
Half life	2 hours
Excretion	Renal (negligible)
Therapeutic considerations
Licence data	US
Pregnancy cat.	D(US)
Legal status	℞-only(US)
Routes	Oral

Vorinostat (rINN) or suberoyl anilide hydroxamic acid (SAHA), brand name Zolinza®, is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new class of agents known as histone deacetylase inhibitors.

Zolinza was approved by the U.S. Food and Drug Administration (FDA) for the treatment of CTCL on October 6, 2006, and it is manufactured by Pantheon, Inc., in Mississauga, Ontario, Canada, for Merck & Co., Inc., White House Station, New Jersey.